Xencor reports positive trial results for inflammatory bowel disease treatment

mirror-images/iStock via Getty Images Xencor ( NASDAQ: XNCR ), on Tuesday, reported positive early results from its first study in humans of XmAb942, an antibody being developed to treat inflammatory bowel diseases like ulcerative colitis and Crohn’s disease. In a dose-escalation study with healthy volunteers, XmAb942 was well tolerated at both single and multiple doses. Based on these results , Xencor plans to begin a Phase 2b trial in patients with moderate-to-severe ulcerative colitis in the second half of 2025.

More on Xencor Xencor, Inc.: No Major Near Term Catalysts Xencor: Substantial Promise, Slow Progress Seeking Alpha’s Quant Rating on Xencor Historical earnings data for Xencor Financial information for Xencor.